Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2024, Payable on and from 4 September, 2024
May 29, 2024 at 02:04 pm IST
Share
Alkem Laboratories Limited at the Board meeting held on May 29, 2024 recommended a final dividend of INR 5 per equity share of INR 2 each for financial year ended March 31, 2024, for the approval of the shareholders of the Company at the upcoming Annual General Meeting. Fixed August 10, 2024 as the record date for the purpose of payment of final dividend. The dividend, if declared by the shareholders, shall be paid on and from 4 September, 2024.
Alkem Laboratories Ltd. is an India-based pharmaceutical company with global operations, engaged in the development, manufacturing and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and international markets. It has a portfolio of more than 800 brands in India. The Company also has a presence in more than 40 international markets, with the United States being its key focus market. Its offerings include therapies, Rx products and Alkem generic. Its therapy offerings include anti-infective, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory, rheumatology and urology. Its product portfolio also includes mega-brands such as Clavam, Pan, Pan-D, and Taxim-O. Under the Alkem Generics cluster there are four divisions: Futura, Maxxio, Novokem and Alkem Healthcare.
ALKEM LABORATORIES LIMITED 
